LAMITOR OD

For the use of a Registered Medical Practitioner or Hospital or a Laboratory only Abbreviated Prescribing information for Lamitor OD (Lamotrigine 50mg, 100mg, 200mg SustainedRelease Tablets I.P.)

[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES:

Mechanism of action: Lamotrigine is an antiepileptic drug belonging from phenylthiazine class. It inhibits sustained repetitive firing of neurones and inhibits release of glutamate (the neurotransmitter which plays a key role in the generation of epileptic seizures). These effects are likely to contribute to the anticonvulsant properties of lamotrigine.

INDICATION: Lamotrigine tablets are indicated as add on therapy of partial and secondary generalised tonic clonic seizures.

DOSAGE AND ADMINISTRATION: Sustained release lamotrigine can be started at 50 mg once a day and dose increments of 50 mg/week can be made if required and maintenance dose is 150 to 250 mg/day given as single daily dose. It can be added to the valproate therapy.

CONTRAINDICATION: It is contraindicated in patients who have demonstrated hypersensitivity (e.g., rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its ingredients.

WARNINGS & PRECAUTIONS: The use of lamotrigine may cause serious skin rashes, DRESS syndrome, blood dyscrasias, increase the risk of suicidal thoughts or behavior. It may bind in the eye and other melanin-containing tissues. Caution should be taken when taking lamotrigine in patients with bipolar disorder. Risk of aseptic meningitis, status epilepticus and potential risk of medication errors. As it may cause withdrawal symptoms, it should not be abruptly discontinued. Sudden Unexplained Death in Epilepsy has also been reported with use of lamotrigine.

DRUG INTERACTIONS: Dosage adjustments will be necessary in most patients who start or stop estrogen-containing oral contraceptives while taking lamotrigine. It also interacts with carbamazepine, phenobarbital/primidone, phenytoin, rifampin and valproate.

ADVERSE REACTIONS: Dizziness, ataxia, somnolence, headache, diplopia, blurred vision, nausea, vomiting, rash, coordination abnormality, dyspepsia, rhinitis, anxiety, insomnia, infection, pain, weight decrease, chest pain, and dysmenorrhea. lymphadenopathy, edema, somnolence, bronchitis, arthralgia, amnesia, urinary frequency, allergic reaction, aspartate transaminase increased, arthritis, confusion and paresthesia.

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,

Ahmedabad-380 009, INDIA

IN/ LAMITOR OD 50,100,200mg/Apr 2021/02/ABPI (Additional information is available on request)